AeternaZentaris Inc. (AEZS) stock prices were up by a marginal 0.43% as of market close on April 23rd, 2021, bringing the price per share up to USD$0.9353 at the end of the trading day. Subsequent pre-market fluctuations saw the price rise by a significant 14.40%, bringing the price per share up to USD$1.07.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Collaboration with Queensland University
Earlier in the year, AEZS signed a material transfer agreement with the University of Queensland that would see the furthering of macimorelin as a therapeutic treatment. This agreement provides AEZS with the future opportunity to negotiate the licensing of any intellectual property developed by the University of Queensland in the development of the macimorelin-based treatment of an undisclosed neurodegenerative disease.
Proliferation of Macimorelin
The company also entered multiple licensing agreements with universities across Europe. These agreements develop pipelines to expand AEZS assets currently in development. AEZS also announced its concrete steps to commercialize macimorelin in a collaboration with Consilient Health Ltd. that saw both companies entering into an exclusive European licensing agreement. The development and commercialization of macimorelin in North America has also been facilitated by the recent amendment to an existing License Agreement with Novo Nordisk Biopharm Ltd.
Collaboration with Julius-Maximilians-University
February 2021 saw AEZS enter into an exclusive option agreement with Julius-Maximilians-University in the development of a potential Covid-19 vaccine with an evaluation of its pre-clinical stage. March 2021 saw the company being granted an exclusive and global license to patents and knowledge owned by the University. This license enables AEZS to conduct Research and Development, commence manufacturing, and plan for commercial sales of the potential vaccine.
Capital Generation
In 2021 alone, the company has hitherto generated significant capital that will facilitate these projects that are currently in the works. A public offering saw AEZS raise USD$31 million in net proceeds, and another USD$20 million from the exercising of warrants.
Strong Financials Reported
Revenues reported for Q4 2020 were reported at a promising USD$2.4 million, a huge increase from the USD$0.02 million reported in the same quarter of the previous year. Of the USD$2.4 million, USD$1.4 million was generated through product sales; USD$0.9 million was attributed to licensing revenue; USD$0.02 million was raised from the collection of royalties, and the remaining USD$0.1 million being generated as a result of supply chain revenue.
Future Outlook for AEZS
With such promising developments in the works and the companies foray into the development of a vaccine for the pandemic that has gripped and crippled the global economy, the future looks bright for AEZS. Strong financial reports inspire confidence in investors who look to the company to pave the way for a lucrative 2021 and beyond.
